Gamida Cell Ltd. (NASDAQ:GMDA) Receives Average Recommendation of “Buy” from Brokerages

Shares of Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) have been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.00.

Several research analysts recently commented on the stock. JMP Securities reiterated a “buy” rating and set a $17.00 price objective on shares of Gamida Cell in a research note on Tuesday, February 1st. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Gamida Cell in a research note on Wednesday, March 16th. Finally, Zacks Investment Research lowered shares of Gamida Cell from a “buy” rating to a “hold” rating in a research note on Monday, April 4th.

Shares of GMDA traded up $0.05 during mid-day trading on Tuesday, hitting $2.37. The company’s stock had a trading volume of 2,797 shares, compared to its average volume of 959,033. The company’s 50-day moving average is $3.51 and its 200-day moving average is $3.21. Gamida Cell has a 52-week low of $2.10 and a 52-week high of $7.09. The firm has a market capitalization of $140.30 million, a price-to-earnings ratio of -1.64 and a beta of 1.82. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 1.63.

Gamida Cell (NASDAQ:GMDA – Get Rating) last posted its quarterly earnings data on Tuesday, March 15th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same quarter in the prior year, the business posted ($0.68) EPS. As a group, sell-side analysts predict that Gamida Cell will post -1.18 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Parametric Portfolio Associates LLC increased its stake in shares of Gamida Cell by 10.7% in the fourth quarter. Parametric Portfolio Associates LLC now owns 32,230 shares of the company’s stock worth $82,000 after acquiring an additional 3,105 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Gamida Cell in the third quarter worth $39,000. Cubist Systematic Strategies LLC increased its stake in shares of Gamida Cell by 54.5% in the third quarter. Cubist Systematic Strategies LLC now owns 33,523 shares of the company’s stock worth $131,000 after acquiring an additional 11,821 shares during the period. Stifel Financial Corp acquired a new stake in shares of Gamida Cell in the fourth quarter worth $37,000. Finally, Royal Bank of Canada increased its stake in shares of Gamida Cell by 21.0% in the third quarter. Royal Bank of Canada now owns 90,726 shares of the company’s stock worth $356,000 after acquiring an additional 15,745 shares during the period. Institutional investors and hedge funds own 47.12% of the company’s stock.

Gamida Cell Company Profile (Get Rating)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Further Reading